CUA Educational Content

PRIME – Prostate Cancer: Regional Insights and Multidisciplinary Excellence

Speakers: Michael Chang, Kim Chi & Michael Ong

Objectives

By participating in this learning program, healthcare providers will be able to:

  • Understand the latest testing and treatment considerations for advanced prostate cancer (PCa) patients with genetic mutations, including those with HRR and MMR mutations.
  • Navigate complex advanced PCa cases across diverse healthcare settings.
  • Leverage multi-disciplinary insights on effective adverse event management.
  • Employ strategies to optimize multidisciplinary patient care plans.
Start Quiz for Credits

ACCREDITATION

This activity is an Accredited Self-Assessment Program (Section 3) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada, and approved by CUA. You may claim a maximum of 2 hours of credit.

This program has received financial support from AstraZeneca/Merck Alliance in the form of an educational grant.

The Canadian Urological Association (CUA) does not provide professional medical advice, diagnosis or treatment and cannot respond to requests for direct feedback, specific patient information or physician referrals. You should first always seek the advice of your urologist, physician and other qualified health provider with any questions regarding your medical condition. The contents of the CUA Website such as text, graphics, images, and other content are for informational purposes only. The content/information is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Never disregard professional medical advice or delay in seeking it because of something you have read on the CUA website.

For comments or information, email Corporate.office@cua.org

Privacy Policy